Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma is the second most common hematological malignancy and while patients can have long responses to therapy, most patients will eventually develop treatment-resistant disease. Over the last thirty years, improved understanding of multiple myeloma and therapeutic advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Ackley, James, Ochoa, Miguel Armenta, Ghoshal, Delta, Roy, Krishnendu, Lonial, Sagar, Boise, Lawrence H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507631/
https://www.ncbi.nlm.nih.gov/pubmed/34638271
http://dx.doi.org/10.3390/cancers13194787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507631/
https://www.ncbi.nlm.nih.gov/pubmed/34638271
http://dx.doi.org/10.3390/cancers13194787

Ejemplares similares